Why NovoCure Stock Soared 32% in July
Why NovoCure Stock Soared 32% in July Shares of NovoCure (NASDAQ:NVCR), rocketed 31. higher Why NovoCure Stock in July, the 500 returned 1. 4% month. NovoCure stock has on a tear in versus the broader market's 3% return. We can NovoCure stock's strong July in part a of the upward momentum enjoyed for some time to a spate of good In May," as I wrote. Optune was already marketed in the United and select international markets treat glioblastoma (GBM). In May 2019, the U. S. Food and Drug Administration (FDA) approved a new treatment for malignant pleural mesothelioma (MPM). It’s the first mesothelioma treatment introduced in 15 years. Manufactured by Novocure, the NovoTTF-100L is the newest treatment option for MPM since Pemetrexed. Also known as Alimta, Pemetrexed was approved in 2004. The new mesothelioma treatment consists of a tumor treating fields (TTF) device used in combination with Pemetrexed plus platinum-based chemotherapy. The TTF device uses elect...